Page results
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
Among the many cancer clinical trials opening each year at UCLH, this year will see a focus on trials of personalised cancer treatments based on precision immunotherapies.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
UCLH will play a vital role in a new respiratory virus study.
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
UCLH has declared a climate and health emergency, and has published a 10-point climate action plan to reach net zero carbon dioxide emissions by 2031.
-
The diabetes team have revisited their tips for managing diabetes over the Christmas holidays and updated them for 2022.
-
Information about our UCLH Charity, charity funds and associated charities.
-
Our staff have rated UCLH as the top trust in England, improving on our ranking from last year when we were third best in England and top in London.
-
UCLH is the first NHS trust to pilot a personalised educational package for patients living with stroke.
File results
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer